Raymond James analyst John Ransom upgraded Aveanna (AVAH) to Outperform from Market Perform with a $9 price target The company reported Q2 results that were well above guidance and consensus forecasts, the analyst tells investors in a research note. The firm sees further deleveraging of Aveanna’s balance sheet as the company’s EBITDA grows and free cash flow is applied to debt reduction. The stock’s current valuation has upside based on the low-double-digit multiples from the higher quality post-acute providers, contends Raymond James.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVAH:
- Aveanna Healthcare Highlights Strong Financial Performance
- Aveanna Healthcare Reports Strong Q2 Growth and Raises 2025 Outlook
- Apple invests extra $100B in U.S., Trump wants Intel CEO to resign: Morning Buzz
- Aveanna Healthcare Reports Strong Q2 2025 Financial Growth
- Aveanna reports Q2 adjusted EPS 18c, consensus 4c